Sinopharma
Sinopharma Sinopharm has expanded its business scale
Sinopharm is a core enterprise of China National Pharmaceutical Group Corporation (ranked 199th in the Fortune 500), founded in January 2003 and listed in Hong Kong (01099.HK) in September 2009. Over the past ten years since its establishment, Sinopharm has expanded its business scale, improved its operation quality and grown its profitability. It has developed into a leading distributor and retailer of pharmaceuticals and healthcare products in China and a leading supply chain service provider, forming an integrated industrial chain with the synergistic development of distribution, retail treatment, chemical reagents, medical devices and healthcare services in the pharmaceutical and healthcare sectors.
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
East China medicine "liraglutide" goes to sea
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Yanye new crown drug 3CL protein inhibitor has been suspended approval
CelcomDigi Berhad and AmBank Sign MOU to Drive Digital Healthcare Transformation
CelcomDigi Berhad today announced the signing of a three-year Memorandum of Understanding (MoU) with AmBank (M) Berhad and AmBank Islamic Berhad, with the aim of empowering healthcare providers in Malaysia through digital healthcare solutions.
Oct 29, 2024 05:36 PM
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
Mojia biology announced the completion of round B financing
First class recall of Draeger, a ventilator giant